CN104349790A - 用于治疗糖尿病的葡萄糖激酶活化剂组合物 - Google Patents
用于治疗糖尿病的葡萄糖激酶活化剂组合物 Download PDFInfo
- Publication number
- CN104349790A CN104349790A CN201380024802.XA CN201380024802A CN104349790A CN 104349790 A CN104349790 A CN 104349790A CN 201380024802 A CN201380024802 A CN 201380024802A CN 104349790 A CN104349790 A CN 104349790A
- Authority
- CN
- China
- Prior art keywords
- officinal salt
- glucokinase activators
- antidiabetic medicine
- diabetes
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Description
组别 | 治疗(po;qd) | n |
A | 载体 | 8 |
B | FRI-1(25mg/kg,口服) | 8 |
C | FRI-1(75mg/kg,口服) | 8 |
D | 二甲双胍(100mg/kg,口服) | 9 |
E | FRI-1(25mg/kg,口服)+二甲双胍(100mg/kg,口服) | 8 |
F | FRI-1(75mg/kg,口服)+二甲双胍(100mg/kg,口服) | 8 |
Claims (23)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261648110P | 2012-05-17 | 2012-05-17 | |
US61/648,110 | 2012-05-17 | ||
PCT/US2013/041076 WO2013173417A2 (en) | 2012-05-17 | 2013-05-15 | Glucokinase activator compositions for the treatment of diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104349790A true CN104349790A (zh) | 2015-02-11 |
Family
ID=48576527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380024802.XA Pending CN104349790A (zh) | 2012-05-17 | 2013-05-15 | 用于治疗糖尿病的葡萄糖激酶活化剂组合物 |
Country Status (16)
Country | Link |
---|---|
US (3) | US10004782B2 (zh) |
EP (1) | EP2849776B1 (zh) |
JP (1) | JP6234443B2 (zh) |
KR (2) | KR20150013838A (zh) |
CN (1) | CN104349790A (zh) |
AU (2) | AU2013262895A1 (zh) |
BR (1) | BR112014028622A2 (zh) |
CA (1) | CA2872021C (zh) |
EA (1) | EA201492109A1 (zh) |
ES (1) | ES2878001T3 (zh) |
HK (1) | HK1202458A1 (zh) |
IL (1) | IL235484A0 (zh) |
IN (1) | IN2014DN09554A (zh) |
MX (1) | MX360304B (zh) |
SG (2) | SG10201609644UA (zh) |
WO (1) | WO2013173417A2 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019228362A1 (zh) * | 2018-05-31 | 2019-12-05 | 华领医药技术(上海)有限公司 | 含葡萄糖激酶激活剂和双胍类降糖药物的药物组合、组合物和复方制剂及其制备方法和用途 |
CN112040945A (zh) * | 2018-06-12 | 2020-12-04 | Vtv治疗有限责任公司 | 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 |
RU2780377C2 (ru) * | 2018-05-31 | 2022-09-22 | Хуа Медсин (Шанхай) Лтд. | Фармацевтическая комбинация, композиция и комбинированный состав, содержащий активатор глюкокиназы и бигуанидное гипогликемическое лекарственное средство, а также способ их приготовления и их применение |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA032085B1 (ru) | 2010-05-26 | 2019-04-30 | виТиви ТЕРАПЬЮТИКС ЭлЭлСи | Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы |
JP6234443B2 (ja) * | 2012-05-17 | 2017-11-22 | ブイティーブイ・セラピューティクス・エルエルシー | 糖尿病治療のためのグルコキナーゼ活性化因子組成物 |
KR102408480B1 (ko) | 2018-05-30 | 2022-06-10 | 이삼구 | 당뇨질환의 치료용 조성물 |
US11872221B2 (en) | 2020-01-31 | 2024-01-16 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator |
AU2020426356A1 (en) * | 2020-01-31 | 2022-08-25 | Hua Medicine (Shanghai) Ltd. | Treating treatment-resistant diabetes with glucokinase activator |
US11857536B2 (en) | 2020-06-04 | 2024-01-02 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
WO2021243645A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
KR20230048502A (ko) * | 2020-06-08 | 2023-04-11 | 브이티브이 테라퓨틱스 엘엘씨 | {2-[3-사이클로헥실-3-(트랜스-4-프로폭시-사이클로헥실)-우레이도]-티아졸-5-일설파닐}-아세트산의 염 또는 공결정 및 그의 용도 |
AU2021289591A1 (en) * | 2020-06-08 | 2023-01-19 | Vtv Therapeutics Llc | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof |
CN115350268A (zh) * | 2022-08-24 | 2022-11-18 | 深圳青澜生物技术有限公司 | 一种用于治疗糖尿病的制剂、微针及其制备工艺 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1910166A (zh) * | 2004-01-06 | 2007-02-07 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
CN101258137A (zh) * | 2005-07-08 | 2008-09-03 | 诺沃-诺迪斯克有限公司 | 双环烷基脲葡糖激酶活化剂 |
WO2010107610A1 (en) * | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds |
EP2392575A1 (en) * | 2010-06-04 | 2011-12-07 | LEK Pharmaceuticals d.d. | A novel synthetic approach to ß-aminobutyryl substituted compounds |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT323195B (de) | 1973-03-16 | 1975-06-25 | Hurka Wilhelm | Verfahren zur herstellung neuer salze von biguaniden |
FR2243684B1 (zh) | 1973-09-19 | 1977-01-28 | Semb | |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
AU5325200A (en) * | 1999-06-21 | 2001-01-09 | Eli Lilly And Company | Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes |
US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
MXPA05009059A (es) | 2003-02-26 | 2005-10-19 | Banyu Pharma Co Ltd | Derivados de heteroarilcarbamoilbenceno. |
US7440726B2 (en) * | 2003-07-14 | 2008-10-21 | Sony Corporation | Information providing method for transmitting broadcast signals being received by a user |
AU2003269484A1 (en) | 2003-09-11 | 2005-03-29 | Biocon Limited | Salt of atorvastatin with metformin |
DK1723128T3 (da) | 2004-01-06 | 2013-02-18 | Novo Nordisk As | Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer |
JP2008502658A (ja) * | 2004-06-17 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | 肝臓選択的グルコキナーゼ活性化因子の使用 |
US20060246141A1 (en) | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
US20100028439A1 (en) | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
JP2009500378A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー/エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
CA2614518A1 (en) | 2005-07-08 | 2007-01-18 | Novo-Nordisk A/S | Dicycloalkyl urea glucokinase activators |
JP4960355B2 (ja) | 2005-07-14 | 2012-06-27 | ノボ・ノルデイスク・エー/エス | ウレア型グルコキナーゼ活性化剤 |
WO2008079787A2 (en) | 2006-12-20 | 2008-07-03 | Takeda San Diego, Inc. | Glucokinase activators |
US8138185B2 (en) | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
BRPI0912802A2 (pt) | 2008-05-16 | 2015-10-13 | Takeda San Diego Inc | ativadores de glicoquinase |
CN102105512B (zh) | 2008-07-22 | 2013-01-23 | 株式会社吴羽 | 末端卤基含量降低了的聚芳撑硫醚的制造方法 |
CN105343871A (zh) | 2009-04-16 | 2016-02-24 | 大正制药株式会社 | 药物组合物 |
KR101190957B1 (ko) | 2009-08-25 | 2012-10-15 | 한올바이오파마주식회사 | 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 |
EA032085B1 (ru) * | 2010-05-26 | 2019-04-30 | виТиви ТЕРАПЬЮТИКС ЭлЭлСи | Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы |
JP6234443B2 (ja) * | 2012-05-17 | 2017-11-22 | ブイティーブイ・セラピューティクス・エルエルシー | 糖尿病治療のためのグルコキナーゼ活性化因子組成物 |
CN105050585A (zh) | 2013-03-04 | 2015-11-11 | Vtv治疗有限责任公司 | 稳定的葡萄糖激酶活化剂组合物 |
MX2015011110A (es) | 2013-03-04 | 2015-10-29 | Vtv Therapeutics Llc | Composiciones solidas que comprenden un activador de glucoquinasa y metodos para elaborar y utilizar las mismas. |
-
2013
- 2013-05-15 JP JP2015512779A patent/JP6234443B2/ja active Active
- 2013-05-15 SG SG10201609644UA patent/SG10201609644UA/en unknown
- 2013-05-15 SG SG11201406987UA patent/SG11201406987UA/en unknown
- 2013-05-15 KR KR1020147035545A patent/KR20150013838A/ko active Application Filing
- 2013-05-15 BR BR112014028622A patent/BR112014028622A2/pt not_active Application Discontinuation
- 2013-05-15 CN CN201380024802.XA patent/CN104349790A/zh active Pending
- 2013-05-15 EP EP13726933.8A patent/EP2849776B1/en active Active
- 2013-05-15 IN IN9554DEN2014 patent/IN2014DN09554A/en unknown
- 2013-05-15 ES ES13726933T patent/ES2878001T3/es active Active
- 2013-05-15 KR KR1020217006420A patent/KR102371364B1/ko active IP Right Grant
- 2013-05-15 EA EA201492109A patent/EA201492109A1/ru unknown
- 2013-05-15 CA CA2872021A patent/CA2872021C/en active Active
- 2013-05-15 MX MX2014013105A patent/MX360304B/es active IP Right Grant
- 2013-05-15 WO PCT/US2013/041076 patent/WO2013173417A2/en active Application Filing
- 2013-05-15 AU AU2013262895A patent/AU2013262895A1/en not_active Abandoned
- 2013-11-05 US US14/071,976 patent/US10004782B2/en active Active
-
2014
- 2014-11-03 IL IL235484A patent/IL235484A0/en unknown
-
2015
- 2015-03-31 HK HK15103235.2A patent/HK1202458A1/zh unknown
-
2017
- 2017-06-07 AU AU2017203835A patent/AU2017203835B2/en active Active
-
2018
- 2018-05-18 US US15/983,249 patent/US10588943B2/en active Active
-
2020
- 2020-01-16 US US16/744,956 patent/US10980861B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1910166A (zh) * | 2004-01-06 | 2007-02-07 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
CN101258137A (zh) * | 2005-07-08 | 2008-09-03 | 诺沃-诺迪斯克有限公司 | 双环烷基脲葡糖激酶活化剂 |
WO2010107610A1 (en) * | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds |
EP2392575A1 (en) * | 2010-06-04 | 2011-12-07 | LEK Pharmaceuticals d.d. | A novel synthetic approach to ß-aminobutyryl substituted compounds |
Non-Patent Citations (1)
Title |
---|
R.J. HINKLIN, ET AL.: "ARRY-403, a glucokinase activator with potent glucose-dependent anti-hyperglycaemic activity in animal models of type 2 diabetes mellitus", 《 DIABETOLOGIA》 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3804715A4 (en) * | 2018-05-31 | 2022-05-25 | Hua Medicine (Shanghai) Ltd. | PHARMACEUTICAL COMBINATION, COMPOSITION AND COMBINATION PREPARATION WITH GLUCOKINASE ACTIVATOR AND DPP-IV INHIBITOR, PROCESS FOR THEIR PREPARATION AND ITS USE |
CN110548147B (zh) * | 2018-05-31 | 2022-01-14 | 华领医药技术(上海)有限公司 | 含有葡萄糖激酶激活剂和dpp-iv抑制剂的药物组合及其制备方法和用途 |
CN110548146A (zh) * | 2018-05-31 | 2019-12-10 | 华领医药技术(上海)有限公司 | 含葡萄糖激酶激活剂和双胍类降糖药物的药物组合、组合物和复方制剂及其制备方法和用途 |
CN110548147A (zh) * | 2018-05-31 | 2019-12-10 | 华领医药技术(上海)有限公司 | 含有葡萄糖激酶激活剂和dpp-iv抑制剂的药物组合及其制备方法和用途 |
RU2770775C1 (ru) * | 2018-05-31 | 2022-04-21 | Хуа Медсин (Шанхай) Лтд. | Фармацевтическая комбинация, композиция и комбинированный состав, содержащий активатор глюкокиназы и ингибитор dpp-iv, и способ его приготовления и применения |
CN110548146B (zh) * | 2018-05-31 | 2022-01-14 | 华领医药技术(上海)有限公司 | 含葡萄糖激酶激活剂和双胍类降糖药物的药物组合、组合物和复方制剂及其制备方法和用途 |
WO2019228365A1 (zh) * | 2018-05-31 | 2019-12-05 | 华领医药技术(上海)有限公司 | 含有葡萄糖激酶激活剂和dpp-iv抑制剂的药物组合、组合物和复方制剂及其制备方法和用途 |
CN114159570A (zh) * | 2018-05-31 | 2022-03-11 | 华领医药技术(上海)有限公司 | 含有葡萄糖激酶激活剂和dpp-iv抑制剂的药物组合及其制备方法和用途 |
US11963947B2 (en) | 2018-05-31 | 2024-04-23 | Hua Medicine (Shanghai) Ltd. | Pharmaceutical combination, composition and compound preparation comprising glucokinase activator and DPP-IV inhibitor, and preparation method and use thereof |
TWI765157B (zh) * | 2018-05-31 | 2022-05-21 | 大陸商華領醫藥技術(上海)有限公司 | 含葡萄糖激酶啟動劑和α-葡萄糖苷酶抑制劑的藥物組合及其製備方法和用途 |
EP3804714A4 (en) * | 2018-05-31 | 2022-05-25 | Hua Medicine (Shanghai) Ltd. | PHARMACEUTICAL COMBINATION AND COMPOSITION AND COMBINATION PREPARATION OF GLUCOKINASE ACTIVATOR AND HYPOGLYCEMIC BIGUANIDE DRUG, AND METHOD OF MANUFACTURE AND USE THEREOF |
EP3811939A4 (en) * | 2018-05-31 | 2022-05-25 | Hua Medicine (Shanghai) Ltd. | PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING A GLUCOSIDASE ACTIVATOR AND A &X3B1;-GLUCOSIDASE INHIBITOR, METHODS OF PREPARING THEM AND USES THEREOF |
WO2019228362A1 (zh) * | 2018-05-31 | 2019-12-05 | 华领医药技术(上海)有限公司 | 含葡萄糖激酶激活剂和双胍类降糖药物的药物组合、组合物和复方制剂及其制备方法和用途 |
RU2780377C2 (ru) * | 2018-05-31 | 2022-09-22 | Хуа Медсин (Шанхай) Лтд. | Фармацевтическая комбинация, композиция и комбинированный состав, содержащий активатор глюкокиназы и бигуанидное гипогликемическое лекарственное средство, а также способ их приготовления и их применение |
TWI794503B (zh) * | 2018-05-31 | 2023-03-01 | 大陸商華領醫藥技術(上海)有限公司 | 含有葡萄糖激酶啟動劑和dpp-iv抑制劑的藥物組合及其製備方法和用途 |
CN112040945A (zh) * | 2018-06-12 | 2020-12-04 | Vtv治疗有限责任公司 | 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 |
Also Published As
Publication number | Publication date |
---|---|
MX360304B (es) | 2018-10-29 |
CA2872021C (en) | 2022-08-16 |
AU2017203835A1 (en) | 2017-06-22 |
KR102371364B1 (ko) | 2022-03-07 |
AU2017203835B2 (en) | 2018-11-22 |
CA2872021A1 (en) | 2013-11-21 |
US10588943B2 (en) | 2020-03-17 |
WO2013173417A3 (en) | 2014-02-20 |
US20180311314A1 (en) | 2018-11-01 |
IN2014DN09554A (zh) | 2015-07-17 |
US10980861B2 (en) | 2021-04-20 |
EA201492109A1 (ru) | 2015-07-30 |
HK1202458A1 (zh) | 2015-10-02 |
JP2015517525A (ja) | 2015-06-22 |
US20140066372A1 (en) | 2014-03-06 |
BR112014028622A2 (pt) | 2017-06-27 |
WO2013173417A2 (en) | 2013-11-21 |
ES2878001T3 (es) | 2021-11-18 |
IL235484A0 (en) | 2014-12-31 |
AU2013262895A1 (en) | 2014-11-13 |
US20200138909A1 (en) | 2020-05-07 |
SG11201406987UA (en) | 2014-12-30 |
KR20210027547A (ko) | 2021-03-10 |
EP2849776A2 (en) | 2015-03-25 |
KR20150013838A (ko) | 2015-02-05 |
US10004782B2 (en) | 2018-06-26 |
JP6234443B2 (ja) | 2017-11-22 |
SG10201609644UA (en) | 2017-01-27 |
EP2849776B1 (en) | 2021-04-21 |
MX2014013105A (es) | 2015-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104349790A (zh) | 用于治疗糖尿病的葡萄糖激酶活化剂组合物 | |
CN101137368B (zh) | 治疗糖尿病的罗氟司特 | |
EP1741445B1 (en) | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | |
Thaipitakwong et al. | A randomized controlled study of dose-finding, efficacy, and safety of mulberry leaves on glycemic profiles in obese persons with borderline diabetes | |
CN103945841A (zh) | 用于保护胰岛细胞的四氢次***酚(thcv) | |
Gökçay Canpolat et al. | Glucose lowering treatment modalities of type 2 diabetes mellitus | |
KR101567660B1 (ko) | 진성 당뇨병을 치료하기 위한 병용제 | |
CN102858155A (zh) | 使用双醋瑞因作为糖尿病的辅助治疗的方法 | |
KR20230143978A (ko) | 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제 | |
CN103417971A (zh) | 二肽基肽酶抑制剂和b族维生素的药物组合物及用途 | |
CN117835981A (zh) | 控制血糖水平和治疗糖尿病及相关疾患的方法 | |
JP4230524B2 (ja) | 2型糖尿病治療用の併用医薬 | |
CN103230594A (zh) | α-葡萄糖苷酶抑制剂和B族维生素的药物组合物 | |
CN112641776A (zh) | 一种以二甲双胍或其可药用盐和澳格列汀或其可药用盐为活性成分的药用组合物 | |
Al-Madhagi et al. | Quality Assessment for two Yemeni glimipride brands compared to the original brand | |
CN113559088A (zh) | 一种含二甲双胍和西格列汀的复方降糖药物制剂 | |
Kaku | Liraglutide for the treatment of diabetes mellitus in Japan | |
CN112312923A (zh) | 控制对象的餐后葡萄糖水平的方法和用途 | |
CN103721074A (zh) | 一种药物组合物及其制备方法和用途 | |
CN108236611A (zh) | 两种化合物联合在制备治疗糖尿病药物中的用途 | |
CN107648288A (zh) | 一种降糖药物组合物及用途 | |
CN101756980A (zh) | 一种二甲双胍/米格列醇降糖口服制剂组合物及其制备 | |
Galam Chaitali et al. | A REVIEW: SITAGLIPTIN DIPEPTIDYL PEPTIDASE-4 INHIBITOR | |
MX2012014757A (es) | Composicion farmaceutica de una meglitinida y una tiazolidinediona o sus sales farmaceuticamente aceptables y su uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: North Carolina Applicant after: vTv Therapeutics LLC Address before: North Carolina Applicant before: TRANSTECH PHARMA, Inc. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TRANSFORMATION TECHNOLOGY PHARMA, LLC TO: VTV THERAPEUTICS LLC Free format text: CORRECT: ADDRESS; FROM: |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1202458 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
CB02 | Change of applicant information |
Address after: North Carolina Applicant after: VTVX Holdings I LLC Address before: North Carolina Applicant before: VTV THERAPEUTICS LLC |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151130 Address after: North Carolina Applicant after: vTv Therapeutics LLC Address before: North Carolina Applicant before: VTVX Holdings I LLC |